CD84 is a survival receptor for CLL cells

Oncogene

Volumn 33, Issue 8, 2014, Pages 1006-1016

  Binsky Ehrenreich, I ^a   Marom, A ^a   Sobotta, M C ^a   Shvidel, L ^b   Berrebi, A ^b   Hazan Halevy, I ^c   Kay, S ^c   Aloshin, A ^a   Sagi, I ^a   Goldenberg, D M ^d   Leng, L ^e   Bucala, R ^e   Herishanu, Y ^c   Haran, M ^b   Shachar, I ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; CD74; CD84; MIF; Survival

Indexed keywords

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; APOPTOSIS; BASE SEQUENCE; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SURVIVAL; DNA PRIMERS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84894517040     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.31     Document Type: Article

References (62)

1. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: A bird of a different feather. J Clin Oncol 1999; 17: 399-408
2. Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochimica et biophysica acta 2002; 1542: 1-13
3. Shachar I, Flavell RA. Requirement for invariant chain in B cell maturation and function. Science 1996; 274: 106-108
4. Matza D, Lantner D, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I. Invariant chain induces B cell maturation in a process which is independent of its chaperonic activity. Proc Natl Acad Sci USA 2002; 99: 3018-3023
5. Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends Immunol. 2003; 24: 246-248
6. Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L et al. Cell Surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006; 107: 4807-4816
7. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L et al. Macrophage migration inhibitory factor (MIF) induces B cell survival by activation of a CD74/CD44 receptor complex. J Biol Chem 2008; 283: 2784-2792
8. Gordin M, Tesio M, Cohen S, Gore Y, Lantner F, Leng L et al. c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol 2010; 185: 2020-2031
9. Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N et al. IL-8 secreted in a macrophage migration-inhibitory factor- And CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007; 104: 13408-13413
10. Binsky I, Lantner F, Grabovsky V, Harpaz N, Shvidel L, Berrebi A et al. TAp63 regulates VLA-4 expression and CLL cell migration to the BM in a CD74 dependent manner. J Immunol 2010; 184: 4761-4769
11. Cohen S, Shoshana OY, Zelman-Toister E, Maharshak N, Binsky-Ehrenreich I, Gordin M et al. The cytokine midkine and its receptor RPTPzeta regulate B cell survival in a pathway induced by CD74. J Immunol 2012; 188: 259-269
12. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004; 104: 3705-3711
13. de laFuente MA, Pizcueta P, Nadal M, Bosch J, Engel P. CD84 leukocyte antigen is a new member of the Ig superfamily. Blood 1997; 90: 2398-2405
14. Martin M, Romero X, de la Fuente MA, Tovar V, Zapater N, Esplugues E et al. CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: Adhesion is mediated by Ig-like domain 1. J Immunol 2001; 167: 3668-3676
15. Romero X, Zapater N, Calvo M, Kalko SG, de la Fuente MA, Tovar V et al. CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-Terminal domain and relocalizes to the immunological synapse. J Immunol 2005; 174: 7033-7042
16. Yan QR, Malashkevich VN, Fedorov A, Fedorov E, Cao E, Lary JW et al. Structure of CD84 provides insight into SLAM family function. Proc Natl Acad Sci USA 2007; 104: 10583-10588
17. Cocks BG, Chang CCJ, Carballido JM, Yssel H, Devries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995; 376: 260-263
18. Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 2003; 3: 813-821
19. Veillette A, Latour S. The SLAM family of immune-cell receptors. Curr Opin Immunol 2003; 15: 277-285
20. Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 2005; 203: 180-199
21. Latour S, Veillette A. The SAP family of adaptors in immune regulation. Semin Immunol 2004; 16: 409-419
22. Tangye SG, Van De Weerdt BCM, Avery DT, Hodgkin PD. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. Eur J Immunol 2002; 32: 1640-1649
23. Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol 2006; 6: 56-66
24. Cannons JL, Qi H, Lu KT, Dutta M, Gomez-Rodriguez J, Cheng J et al. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving ntegrins SLAM-Associated Protein, and CD84. Immunity 2010; 32: 253-265
25. Palou E, Pirotto F, Sole J, Freed JH, Peral B, Vilardell C et al. Genomic characterization of CD84 reveals the existence of five isoforms differing in their cytoplasmic domains. Tissue Antigens 2000; 55: 118-127
26. Dios A, Mitchell RA, Aljabari B, Lubetsky J, O'Connor K, Liao H et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 2002; 45: 2410-2416
27. Nagy N, Cerboni C, Mattsson K, Maeda A, Gogolak P, Sumegi J et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer 2000; 88: 439-447
28. Morra M, Lu J, Poy F, Martin M, Sayos J, Calpe S et al. Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J 2001; 20: 5840-5852
29. Calpe S, Erdos E, Liao GX, Wang NH, Rietdijk S, Simarro M et al. Identification and characterization of two related murine genes, Eat2a and Eat2b, encoding single SH2-domain adapters. Immunogenetics 2006; 58: 15-25
30. Inabe K, Kurosaki T. Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood 2002; 99: 584-589
31. Oliver-Vila I, Saborit-Villarroya I, Engel P, Martin M. The leukocyte receptor CD84 inhibits Fc epsilon RI-mediated signaling through homophilic interaction in transfected RBL-2H3 cells. Mol Immunol 2008; 45: 2138-2149
32. Nanda N, Andre P, Bao M, Clauser K, Deguzman F, Howie D et al. Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. Blood 2005; 106: 3028-3034
33. Durig J, Ebeling P, Grabellus F, Sorg UR, Mollmann M, Schutt P et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007; 67: 8653-8661
34. Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009; 69: 3121-3130
35. Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 1998; 103: 335-342
36. Meyer-Siegler K, Hudson PB. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 1996; 48: 448-452
37. Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N et al. Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread. Jpn J Cancer Res 2002; 93: 389-396
38. Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S. Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-Associated angiogenesis. Ann NY Acad Sci 2003; 995: 171-182
39. Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999; 5: 181-191
40. Bifulco C, McDaniel K, Leng L, Bucala R. Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des 2008; 14: 3790-3801
41. Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 2004; 4: 34-45
42. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Iwashige H, Aridome K et al. Invariant chain expression in gastric cancer. Cancer Lett 2001; 168: 87-91
43. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA et al. Expression profiling of renal epithelial neoplasms: A method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001; 158: 1639-1651
44. Ioachim HL, Pambuccian SE, Hekimgil M, Giancotti FR, Dorsett BH. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol 1996; 20: 64-71
45. Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-Associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 2000; 8: 210-215
46. Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer 1997; 79: 2115-2124
47. Narni F, Kudo J, Mars W, Calabretta B, Florine DL, Barlogie B et al. HLA-DRassociated invariant chain is highly expressed in chronic lymphocytic leukemia. Blood 1986; 68: 372-377
48. Veenstra H, Jacobs P, Dowdle EB. Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia. Cell Immunol 1996; 171: 68-73
49. Mizue Y, Nishihira J, Miyazaki T, Fujiwara S, Chida M, Nakamura K et al. Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: Elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int J Mol Med 2000; 5: 397-403
50. Howie D, Simarro M, Sayos J, Guirado M, Sancho J, Terhorst C. Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation. Blood 2002; 99: 957-965
51. Haran M, Chebatco S, Flaishon L, Lantner F, Harpaz N, Valinsky L et al. Grb7 expression and cellular migration in chronic lymphocytic leukemia: A comparative study of early and advanced stage disease. Leukemia 2004; 18: 1948-1950
52. Kay S, Herishanu Y, Pick M, Rogowski O, Baron S, Naparstek E et al. Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome. Cytometry B Clin Cytom 2006; 70B: 218-226
53. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456
54. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997
55. Bernhagen J, Mitchell RA, Calandra T, Voelter W, Cerami A, Bucala R. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 1994; 33: 14144-14155
56. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J et al. CD74: A new candidate target for the immunotherapy of B-Cell neoplasms. Clin Cancer Res 2007; 13: 5556S-5563S.
57. Matza D, Kerem A, Lantner F, Shachar I. Invariant chain induced B cell differentiation requires intramembrane - proteolytic release of the cytosolic domain. Immunity 2002; 17: 549-560
58. Flaishon L, Becker-Herman S, Hart G, Levo Y, Kuziel WA, Shachar I. Expression of the Chemokine Receptor CCR2 on Immature B cells Negatively Regulates their Cytoskeletal Rearrangement and Migration. Blood 2004; 104: 933-941
59. Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004; 24: 579-590
60. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J et al. MIF Signal Transduction Initiated by Binding to CD74. J Exp Med 2003; 197: 1467-1476
61. Matza D, Wolstein O, Dikstein R, Shachar I. Invariant Chain Induces B Cell Maturation by Activating TAFII105-NF-kB Dependent Transcription Program. J Biol Chem 2001; 276: 27203-27206
62. Ho MK, Springer TA. Preparation and use of monoclonal antimacrophage antibodies. Methods Enzymol 1984; 108: 313-324.